The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze)., and Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Integrated approaches to improve prognosis prediction in multiple myeloma
In this video, Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the development of novel integrated approaches and tools to improve prognosis prediction in multiple myeloma (MM). These approaches integrate information from molecular profiling, next-generation imaging, and clinical genomic data, with the ultimate goal of personalizing treatment for patients. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In last years, we have seen a great diagnostic and therapeutic revolution in multiple myeloma. However, it’s time to in some way concentrate on how we can improve the personalization of the treatment for our patients. And in our institution, we are developing a multi-omic study in which we are integrating molecular profiling of our patients according to gene expression profiling with SKY92 together with a new generation imaging, full body MRI combined to PET-CT with FDG in all our consecutive patients together with metabolomic characteristics and in general a lot of clinical genomic data...
In last years, we have seen a great diagnostic and therapeutic revolution in multiple myeloma. However, it’s time to in some way concentrate on how we can improve the personalization of the treatment for our patients. And in our institution, we are developing a multi-omic study in which we are integrating molecular profiling of our patients according to gene expression profiling with SKY92 together with a new generation imaging, full body MRI combined to PET-CT with FDG in all our consecutive patients together with metabolomic characteristics and in general a lot of clinical genomic data. And we are performing like a prognostic score that is going to better stratify our patients and in some way to develop some biomarkers in order at first to understand who is the patient with the better or poorer prognosis but also in some way to understand in the next future which will be the good biomarker for a personalized driven approach and this is our real endpoint for this study.
In this moment we are presenting in a separate way the imaging part and the molecular part like we have seen this is our new update with molecular data at this ASH 2025 in Orlando, but we are going to integrate soon according also to artificial intelligence and radiomic tools the data from radiology and molecular pathway and I think that we are going to see really interesting data from our monocentric institutional study, but we are going also to integrate data from other institutions and I hope hopefully in the next future to develop a network in order to integrate our data with the main national institutions in the treatment of multiple myeloma. However I think that in last years we have seen many drug approvals but it’s really time to understand which is the best drug or the best combination for every patient in order to optimize the treatment but also in order to understand who is the patient in which maybe we can stop the treatment and only watch and wait and in general for the next future to cure our patients and this is our real dream and the best wish that we give to our patients, to their caregivers and to all myeloma researchers.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
